Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

Introduction Approximately 10% of EGFR mutations (EGFRmuts) are uncommon
(ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with …

Introduction This integrated analysis of a phase 1/2 study (NCT03046992) assessed the
efficacy and safety of lazertinib, a third-generation epidermal growth factor receptor (EGFR) …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

Lung cancer is the leading cause of cancer-related mortality worldwide. Detectable driver
mutations have now changed the course of lung cancer treatment with the emergence of …

Background Osimertinib is selective for both epidermal growth factor receptor (EGFR)-
tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. While intracranial …

Despite the recent development of precision medicine and targeted therapies, lung cancer
remains the top cause of cancer-related mortality worldwide. The patients diagnosed with …

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic
management has advanced to identify various critical oncogenic mutations that promote …

Background: Although the clinical application of osimertinib, a third-generation epidermal
growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been a new step forward in …